Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809359 | 0.88 | ALOX15 (0.59) | ALOX15KCNK3KCNK9LMNAGPR35 | |
| SCHEMBL6175474 | 0.85 | LMNA (0.56) | LMNAKDM4EKMT2AGAAATM | |
| SCHEMBL1811362 | 0.85 | ALOX15 (0.50) | ALOX15LMNAGPR35KDM4EGAA | |
| SCHEMBL6177730 | 0.84 | CTNNB1 (0.37) | ALOX15KCNK3KCNK9LMNAKDM4E | |
| SCHEMBL6177263 | 0.84 | LMNA (0.48) | LMNAKDM4EKMT2AGAAATM | |
| SCHEMBL6177423 | 0.83 | APP (0.37) | KCNK3KCNK9LMNAKDM4EKMT2A | |
| SCHEMBL1809520 | 0.81 | ALOX15 (0.47) | ALOX15LMNAGPR35KDM4EKMT2A | |
| SCHEMBL1809185 | 0.78 | PDK2 (0.49) | ALOX15LMNAGPR35KDM4EKMT2A | |
| SCHEMBL7697377 | 0.77 | LMNA (0.48) | KCNK3KCNK9LMNAKDM4EKMT2A | |
| SCHEMBL6177510 | 0.76 | KDM4E (0.45) | KDM4EKMT2AGAAATMPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559709-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | Eisai Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
| EP-0838453-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2005-04-27 | — | — | EP | disclosed |
| US-6884808-B2 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| US-6630463-B2 | Such as 4-(4-(2-(2-(5,6,7,8-tetrahydro-5,5,8,8 -tetramethylquinoxalyl))pyrrolyl))benzoic acid; for treatment of acute promyelocytic leukemia | EISAI CO. LTD. (JP) | 2003-10-07 | — | — | US | disclosed |
| US-20030144276-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2003-07-31 | — | — | US | disclosed |
| US-6541474-B2 | Administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or salt to a patient suffering form acute promyelocytic leukemia | EISAI CO. LTD. (JP) | 2003-04-01 | — | — | US | disclosed |
| US-20020103234-A1 | Heterocycl-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2002-08-01 | — | — | US | disclosed |
| US-20020032202-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2002-03-14 | — | — | US | disclosed |
| US-6329402-B1 | FOR THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA | EISAI CO., LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-5977108-A | LEUKEMIA | EISAI CO., LTD (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0838453-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 1998-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103234-A1 | Heterocycl-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | ALOX15 1229/4885KCNK3 4362/4885KCNK9 3244/4885 |
| US-20030144276-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | ALOX15 1275/4885KCNK3 4364/4885KCNK9 3450/4885 |
| US-20020032202-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | ALOX15 1275/4885KCNK3 4364/4885KCNK9 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.